Xencor Inc Revenue Growth Rates (XNCR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Xencor Inc  (NASDAQ: XNCR)
 

XNCR's Revenue Growth by Quarter and Year

Xencor Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

XNCR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 51.22
1st Quarter March 4.52
FY 55.74

XNCRs Annual Revenue
Xencor Inc's Revenue in the fiscal year 2025 $ 125.58 millions
Xencor Inc's Revenue in the fiscal year 2024 $ 110.49 millions
Xencor Inc's Revenue in the fiscal year 2023 $ 174.62 millions
Xencor Inc's Revenue in the fiscal year 2022 $ 164.58 millions
Xencor Inc's Revenue in the fiscal year 2021 $ 275.11 millions




XNCR Revenue second quarter 2026 Y/Y Growth Comment
Xencor Inc reported Revenue increase of 17.45% year on year in the second quarter 2026, to $ 51.22 millions, this is lower than Xencor Inc's recent average Revenue rise of 80.39%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 71 other companies have achieved higher Revenue growth. While Xencor Inc' s Revenue growth of 17.45% ranks overall at the positon no. 1078 in the second quarter 2026.


XNCR Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -46.51 % 3.57 % 135.86 %
3rd Quarter September - 17.98 % -69.91 % 116.7 %
2nd Quarter June 17.45 % 82.39 % -47.47 % 50.83 %
1st Quarter March -86.19 % 104.56 % -15.61 % -77.82 %
FY   - 13.65 % -36.72 % -

Financial Statements
Xencor Inc's second quarter 2026 Revenue $ 51.22 millions XNCR's Income Statement
Xencor Inc's second quarter 2025 Revenue $ 43.61 millions Quarterly XNCR's Income Statement


XNCR Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 34.48 % 196.57 % -13.84 %
3rd Quarter September - -51.85 % -25.55 % 29.96 %
2nd Quarter June 1033.21 % 33.24 % 49.44 % 140.08 %
1st Quarter March -83.99 % -38 % -68.61 % -12.26 %
FY (Year on Year)   - 13.65 % -36.72 % -


Back to XNCR Growth rate Comparisons >> Back to XNCR Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #72
Healthcare Sector #204
Overall #1078

Revenue Y/Y Growth Statistics
High Average Low
992.56 % 80.39 % -69.98 %
(Jun 30 2016)   (Mar 31 2023)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #72
Healthcare Sector #204
Overall #1078
Revenue Y/Y Growth Statistics
High Average Low
992.56 % 80.39 % -69.98 %
(Jun 30 2016)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Xencor Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1034.21 % 112.09 % -100 %
(Jun 30 2026)  


XNCR's II. Quarter Q/Q Revenue Comment
Xencor Inc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 1033.21%, to $ 51.22 millions, from $4.52 millions in the first quarter.
XNCR is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Revenue quarter on quarter growth. While Xencor Inc's Revenue growth quarter on quarter, overall rank is 30.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #9
Healthcare Sector #12
Overall #30
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #9
Healthcare Sector #12
Overall #30
Revenue Q/Q Growth Statistics
High Average Low
1034.21 % 112.09 % -100 %
(Jun 30 2026)  


XNCR's II. Quarter Q/Q Revenue Comment
Xencor Inc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 1033.21%, to $ 51.22 millions, from $4.52 millions in the first quarter.
XNCR is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Revenue quarter on quarter growth. While Xencor Inc's Revenue growth quarter on quarter, overall rank is 30.


Xencor Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 104.97 $ 97.36 $ 125.58 $ 150.13 $ 146.93
Y / Y Revenue Growth (TTM) -28.56 % -23.48 % 13.65 % 38.16 % -2.07 %
Year on Year Revenue Growth Overall Ranking # 2834 # 2920 # 1953 # 2154 # 318
Seqeuential Revenue Change (TTM) 7.82 % -22.47 % -16.36 % 2.18 % 15.48 %
Seq. Revenue Growth (TTM) Overall Ranking # 1089 # 877 # 1325 # 2168 # 1332


Cumulative Revenue growth Comment
Xencor Inc's cumulative 12 months Revenue continue to drop, but on the faster rate at -28.56% year on year, at Jun 30 2026 compare to the -23.48% decrease at Mar 31 2026. If the Xencor Inc's fiscal year would end at Jun 30 2026, annual Revenue would be $105 millions.

In the Healthcare sector 399 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2834, from total ranking in previous quarter at 2920.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 72
Healthcare Sector # 400
Overall # 2834

Revenue TTM Y/Y Growth Statistics
High Average Low
992.56 %
 80.39 %
-69.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 72
Sector # 205
S&P 500 # 1089
Cumulative Revenue growth Comment
Xencor Inc's cumulative 12 months Revenue continue to drop, but on the faster rate at -28.56% year on year, at Jun 30 2026 compare to the -23.48% decrease at Mar 31 2026. If the Xencor Inc's fiscal year would end at Jun 30 2026, annual Revenue would be $105 millions.

In the Healthcare sector 399 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2834, from total ranking in previous quarter at 2920.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 72
Healthcare Sector # 400
Overall # 2834

Revenue TTM Y/Y Growth Statistics
High Average Low
992.56 %
80.39 %
-69.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 72
Sector # 205
S&P 500 # 1089




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
XNCR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Aclarion Inc 30.48%$ 30.483 millions
Harmony Biosciences Holdings inc 30.42%$ 30.421 millions
Personalis Inc 29.96%$ 29.960 millions
Beone Medicines Ltd 29.69%$ 29.693 millions
Capsovision Inc 29.60%$ 29.598 millions
Intuitive Surgical Inc 29.27%$ 29.272 millions
Xeris Biopharma Holdings Inc 28.74%$ 28.741 millions
Ultragenyx Pharmaceutical Inc 28.53%$ 28.532 millions
Innoviva Inc 28.39%$ 28.391 millions
Electrocore Inc 28.03%$ 28.031 millions
Lightwave Logic Inc 27.91%$ 27.909 millions
American Shared Hospital Services27.15%$ 27.149 millions
Protalix Biotherapeutics inc 27.07%$ 27.066 millions
Alkermes Plc 26.97%$ 26.968 millions
Lucid Diagnostics Inc 26.74%$ 26.741 millions
Lifestance Health Group Inc 26.08%$ 26.076 millions
Ani Pharmaceuticals Inc25.87%$ 25.866 millions
Sight Sciences Inc 25.83%$ 25.830 millions
Grail Inc 25.72%$ 25.723 millions
Fortress Biotech Inc 25.66%$ 25.658 millions
Apyx Medical Corp25.27%$ 25.273 millions
Radnet Inc 24.99%$ 24.986 millions
Precipio inc 24.18%$ 24.178 millions
Krystal Biotech Inc 24.14%$ 24.135 millions
Viemed Healthcare Inc 23.85%$ 23.853 millions
Ardelyx inc 23.77%$ 23.771 millions
Insulet Corporation23.51%$ 23.509 millions
Veracyte Inc 23.45%$ 23.448 millions
Journey Medical Corp23.33%$ 23.326 millions
Twist Bioscience Corporation23.24%$ 23.235 millions


About Xencor Inc Revenue Growth Rates (XNCR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Xencor Inc (CIK 1326732).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001326732-26-000056
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Xencor Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.